Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), DENTSPLY SIRONA (XRAY) and Morphosys Ag (MOR)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Arcturus Therapeutics (ARCT – Research Report), DENTSPLY SIRONA (XRAY – Research Report) and Morphosys Ag (MOR – Research Report).

Arcturus Therapeutics (ARCT)

Wells Fargo analyst Yanan Zhu maintained a Buy rating on Arcturus Therapeutics yesterday and set a price target of $45.00. The company’s shares closed last Friday at $19.58.

According to TipRanks.com, Zhu ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -18.5% and a 31.6% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Gracell Biotechnologies.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcturus Therapeutics with a $72.50 average price target.

See the top stocks recommended by analysts >>

DENTSPLY SIRONA (XRAY)

In a report released today, Nathan Rich from Goldman Sachs maintained a Hold rating on DENTSPLY SIRONA. The company’s shares closed last Friday at $29.21.

According to TipRanks.com, Rich is a 3-star analyst with an average return of 1.0% and a 53.0% success rate. Rich covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals, Elanco Animal Health, and Alignment Healthcare.

Currently, the analyst consensus on DENTSPLY SIRONA is a Moderate Buy with an average price target of $35.00, implying a 21.7% upside from current levels. In a report issued on November 2, J.P. Morgan also maintained a Hold rating on the stock with a $30.00 price target.

Morphosys Ag (MOR)

Wells Fargo analyst Derek Archila maintained a Buy rating on Morphosys Ag today and set a price target of $17.00. The company’s shares closed last Friday at $7.93, close to its 52-week high of $8.67.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 5.4% and a 40.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as Zentalis Pharmaceuticals, Apellis Pharmaceuticals, and Monte Rosa Therapeutics.

Morphosys Ag has an analyst consensus of Strong Buy, with a price target consensus of $13.11.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ARCT:

• Arcturus Therapeutics management to meet with William Blair
• Arcturus Therapeutics partner to receive $165M from Japanese government
• Developers of mRNA Vaccines Honored with Nobel Prize
• 3 Best Stocks to Buy Now, 9/28/2023, According to Top Analysts
• Arcturus and CF Foundation extend pact to advance ARCT-032